AffaMed Therapeutics has received approval from the China’s National Medical Products Administration (NMPA) for its clinical trial application (CTA) of Risuteganib (Luminate) for the treatment of intermediate dry age-related macular degeneration (Dry AMD).

With the approval, the ophthalmic intravitreal injectable product Risuteganib is anticipated to become the first candidate in China to enter Phase III development.

In the study, the efficacy and safety of Risuteganib will be evaluated.

“To date, there is no approved and effective treatment in China for patients suffering from dry AMD, which represents the vast majority of the AMD patient population,” said AffaMed Therapeutics CEO Dr Dayao Zhao.

“We are encouraged by the Chinese regulator’s efficiency in approving our application for this innovative therapy.

“We are looking forward to bringing this innovative treatment to Dry AMD patients in Greater China as soon as possible.”

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

The company signed a licensing agreement with Hanmi Pharmaceutical in December 2021 for the manufacturing, development and commercialisation of Risuteganib in Greater China, including Hong Kong, mainland China, Macau, and Taiwan.

Previously, Hanmi gained exclusive rights from Allegro Ophthalmic for Risuteganib’s development and commercialisation in China and Korea.

Luminate is an integrin regulator that controls several pathways of oxidative stress response such as mitochondrial dysfunction.

In a Phase II proof of concept study, Risuteganib met the primary endpoint of vision improvement in patients with intermediate Dry AMD against placebo.

AffaMed is also engaged in developing pharmaceutical, surgical, and digital products for treating neurological, psychiatric, and ophthalmological disorders.